Abstract
Introduction: Gut bacteria modulate the immune system and influence outcomes of allogeneic hematopoietic cell transplantation (allo-HCT). The presence of Blautia, butyrate-producing Clostridia, and Eubacterium limosum in the stool has been associated with lower mortality after allo-HCT. We previously reported an unexpected association between pre-HCT gut colonization with intrinsically vancomycin-resistant enterococci (iVRE: E. gallinarum and E. casseliflavus) and improved overall survival (OS) due to decreased non-relapse mortality (NRM). In an expanded cohort, now also including patients who were iVRE-colonized early post-HCT (before day +14), we demonstrate that the iVRE association with improved OS is specific to E. casseliflavus.
Patients and Methods: We studied allo-HCT recipients at our institution who had at least 1 positive rectal swab or stool culture for iVRE between days -14 and +14. New admissions for HCT were screened for gut VRE colonization weekly until discharge. SpectraTM VRE chromogenic agar medium (ThermoFisher Scientific) was used for species-level identification. Antimicrobial prophylaxis consisted of levofloxacin, acyclovir, and an azole. Cefepime was our empiric antibiotic for neutropenic fever.
Results: 66 (23 with E. casseliflavus and 43 with E. gallinarum) of the 873 allograft recipients between 2011-2017 met our inclusion criteria. As expected from the constitutive, rather than acquired, vancomycin resistance of iVRE, the groups did not differ in their prior exposure to different classes of antibiotics. There were no significant differences between the groups in patient-, disease-, or transplant-related characteristics, except a higher frequency of sirolimus-based GVHD prophylaxis in the E. casseliflavus group (35% vs. 12%, P = 0.05). With a median follow up of 30 months, OS was significantly better in patients with E. casseliflavus (91% vs. 62% at 3 years, P = 0.04), due to lower NRM (0 vs. 18% at 3 years, P = 0.05) (Figures 1A and 1B). Only 2 patients with E. casseliflavus died within 3 years post-HCT, both due to relapse. In contrast, 14 patients with E. gallinarum died within 3 years post-HCT: 7 (50%) due to relapse, and 7 (50%) from NRM (4 GVHD, 1 infection, 1 graft failure, and 1 veno-occlusive disease). In multivariable analysis, E. casseliflavus gut colonization was significantly associated with reduced all-cause mortality (hazard ratio 0.20, 95% confidence interval 0.04-0.91, P = 0.04). There were no significant differences between the groups in 180-day acute grade II-IV GVHD (P = 0.19), 1-year chronic GVHD (P = 0.56), 100-day bacteremia (P = 0.59), or 100-day Clostridium difficile infection (P = 0.79). To probe the mechanism of this protection against mortality, we mined 15 E. casseliflavus and 8 E. gallinarum sequenced genomes for 14 shikimate and tryptophan metabolism enzymes. This analysis predicted that E. casseliflavus encodes a larger number of enzymes in the tryptophan metabolism pathway (Figure 1C). Several compounds in this pathway are ligands for the aryl hydrocarbon receptor (AhR). Signals downstream of AhR augment the gut barrier and modulate the immune system, potentially reducing pathogenic injury and inducing protective immune responses.
Conclusions: Pre-engraftment gut colonization with E. casseliflavus, but not E. gallinarum, improves survival after allo-HCT. Future mechanistic studies of the interactions between E. casseliflavus and the host can guide the development of novel microbiota-oriented therapeutics in this high-risk patient population.
Disclosures
Weisdorf: Seattle Genetics: Consultancy; FATE: Consultancy; SL Behring: Consultancy; Pharmacyclics: Consultancy; Equillium: Consultancy.
Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party
